Compares two beta blockers in adults receiving hemodialysis for kidney failure
Compares metoprolol succinate and carvedilol in adults on dialysis for kidney failure.
Plain-language title generated from the registry record
Registry title: CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Key facts
- Where
- Albuquerque, Aurora, Boston, Chicago, Dallas, Decatur, Durham, Gainesville, Iowa City, Long Beach, Minneapolis, Omaha, Philadelphia, Pittsburgh, Salisbury, Salt Lake City, Seattle, and West Haven, United StatesSee the 18 sites
- Phase
- Phase 3
Where in United States
- New Mexico VA Health Care System, Albuquerque, NMAlbuquerque, United StatesTaking people
- Rocky Mountain Regional VA Medical Center, Aurora, COAurora, United StatesTaking people
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MABoston, United StatesNot yet recruiting
- Jesse Brown VA Medical Center, Chicago, ILChicago, United StatesTaking people
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TXDallas, United StatesNot yet recruiting
- Atlanta VA Medical and Rehab Center, Decatur, GADecatur, United StatesNot yet recruiting
- Durham VA Medical Center, Durham, NCDurham, United StatesTaking people
- North Florida/South Georgia Veterans Health System, Gainesville, FLGainesville, United StatesTaking people
- Iowa City VA Health Care System, Iowa City, IAIowa City, United StatesTaking people
- VA Long Beach Healthcare System, Long Beach, CALong Beach, United StatesTaking people
- Minneapolis VA Health Care System, Minneapolis, MNMinneapolis, United StatesTaking people
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NEOmaha, United StatesTaking people
- Philadelphia MultiService Center, Philadelphia, PAPhiladelphia, United StatesTaking people
- VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PAPittsburgh, United StatesTaking people
- Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NCSalisbury, United StatesNot yet recruiting
- VA Salt Lake City Health Care System, Salt Lake City, UTSalt Lake City, United StatesTaking people
- VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, United StatesNot yet recruiting
- VA Connecticut Healthcare System West Haven Campus, West Haven, CTWest Haven, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- VA Office of Research and Development
- Trial code
- NCT05931276
- Record updated
- 13 October 2026
- Original description
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.Read full original descriptionShow less
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
Inclusion: On hemodialysis; Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol.
Exclusion: Patients not receiving carvedilol who have a history of asthma; Provider unwilling to sign a new medication order for a randomized patient; known hypersensitivity to any component of either drug; Impaired decision-making capacity; No surrogate consent will be allowed.